{"id":9,"date":"2018-04-01T20:07:52","date_gmt":"2018-04-01T19:07:52","guid":{"rendered":"https:\/\/admin.innaxon.cz\/?page_id=9"},"modified":"2025-08-20T11:54:38","modified_gmt":"2025-08-20T10:54:38","slug":"about-innaxon","status":"publish","type":"page","link":"https:\/\/www.innaxon.cz\/index.php\/about-innaxon\/","title":{"rendered":"About Innaxon"},"content":{"rendered":"\n\n\t<h2><strong>Innaxon, s.r.o. is an early-stage development company based in the Czech Republic.<\/strong><\/h2>\n<p>Innaxon&#8217;s in-house biopharmaceuticals Toll-like Receptor 4 (TLR4) agonists (Dendrophilin\u00ae\u00a0and Novo-Pyrexal\u00ae) and in-licensed small molecule\u00a0inhibitors\u00a0(IAXOTM\u00a0compounds)\u00a0have been shown in proof-of-concept pre-clinical studies to treat\u00a0cancer\u00a0and prevent serious inflammatory diseases, respectively.<\/p>\n\t\t\t\t<img decoding=\"async\" src=\"https:\/\/www.innaxon.cz\/wp-content\/uploads\/2018\/04\/Innaxon-3-2.jpg\" alt=\"SCHOOL BAGPACK low poly gray\" itemprop=\"image\" height=\"750\" width=\"1500\" title=\"SCHOOL BAGPACK low poly gray\" onerror=\"this.style.display='none'\" loading=\"lazy\" \/>\n\t\t\t\t<img decoding=\"async\" src=\"https:\/\/www.innaxon.cz\/wp-content\/uploads\/2021\/02\/Innaxon-sro_3.jpg\" alt=\"Innaxon sro_3\" itemprop=\"image\" height=\"400\" width=\"400\" title=\"Innaxon sro_3\" onerror=\"this.style.display='none'\" loading=\"lazy\" \/>\n\t<p>Innaxon\u00a0continuously seeks further partnerships with academic, pharmaceutical and clinical research centres to harness innate immunity for therapeutic benefit in the field of<\/p>\n<ul>\n<li>vaccine adjuvants<\/li>\n<li>immuno(chemo)therapy<\/li>\n<li>anti-inflammatory agents<\/li>\n<\/ul>\n\n","protected":false},"excerpt":{"rendered":"<p>Innaxon, s.r.o. is an early-stage development company based in the Czech Republic. Innaxon&#8217;s in-house biopharmaceuticals Toll-like Receptor 4 (TLR4) agonists (Dendrophilin\u00ae\u00a0and Novo-Pyrexal\u00ae) and in-licensed small molecule\u00a0inhibitors\u00a0(IAXOTM\u00a0compounds)\u00a0have been shown in proof-of-concept pre-clinical studies to treat\u00a0cancer\u00a0and prevent serious inflammatory diseases, respectively. Innaxon\u00a0continuously seeks further partnerships with academic, pharmaceutical and clinical research centres<\/p>\n<p><a class=\"more-link\" href=\"https:\/\/www.innaxon.cz\/index.php\/about-innaxon\/\">Read More<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-9","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>About Innaxon - Innaxon, s.r.o.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.innaxon.cz\/index.php\/about-innaxon\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"About Innaxon - Innaxon, s.r.o.\" \/>\n<meta property=\"og:description\" content=\"Innaxon, s.r.o. is an early-stage development company based in the Czech Republic. Innaxon&#8217;s in-house biopharmaceuticals Toll-like Receptor 4 (TLR4) agonists (Dendrophilin\u00ae\u00a0and Novo-Pyrexal\u00ae) and in-licensed small molecule\u00a0inhibitors\u00a0(IAXOTM\u00a0compounds)\u00a0have been shown in proof-of-concept pre-clinical studies to treat\u00a0cancer\u00a0and prevent serious inflammatory diseases, respectively. Innaxon\u00a0continuously seeks further partnerships with academic, pharmaceutical and clinical research centresRead More\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.innaxon.cz\/index.php\/about-innaxon\/\" \/>\n<meta property=\"og:site_name\" content=\"Innaxon, s.r.o.\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-20T10:54:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.innaxon.cz\/wp-content\/uploads\/2018\/04\/Innaxon-3-2.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.innaxon.cz\/index.php\/about-innaxon\/\",\"url\":\"https:\/\/www.innaxon.cz\/index.php\/about-innaxon\/\",\"name\":\"About Innaxon - Innaxon, s.r.o.\",\"isPartOf\":{\"@id\":\"https:\/\/www.innaxon.cz\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.innaxon.cz\/index.php\/about-innaxon\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.innaxon.cz\/index.php\/about-innaxon\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.innaxon.cz\/wp-content\/uploads\/2018\/04\/Innaxon-3-2.jpg\",\"datePublished\":\"2018-04-01T19:07:52+00:00\",\"dateModified\":\"2025-08-20T10:54:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.innaxon.cz\/index.php\/about-innaxon\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.innaxon.cz\/index.php\/about-innaxon\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.innaxon.cz\/index.php\/about-innaxon\/#primaryimage\",\"url\":\"https:\/\/www.innaxon.cz\/wp-content\/uploads\/2018\/04\/Innaxon-3-2.jpg\",\"contentUrl\":\"https:\/\/www.innaxon.cz\/wp-content\/uploads\/2018\/04\/Innaxon-3-2.jpg\",\"width\":1500,\"height\":750},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.innaxon.cz\/index.php\/about-innaxon\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.innaxon.cz\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"About Innaxon\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.innaxon.cz\/#website\",\"url\":\"https:\/\/www.innaxon.cz\/\",\"name\":\"Innaxon, s.r.o.\",\"description\":\"Targeting Innate Immunity For Therapeutic Benefit\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.innaxon.cz\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"About Innaxon - Innaxon, s.r.o.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.innaxon.cz\/index.php\/about-innaxon\/","og_locale":"en_GB","og_type":"article","og_title":"About Innaxon - Innaxon, s.r.o.","og_description":"Innaxon, s.r.o. is an early-stage development company based in the Czech Republic. Innaxon&#8217;s in-house biopharmaceuticals Toll-like Receptor 4 (TLR4) agonists (Dendrophilin\u00ae\u00a0and Novo-Pyrexal\u00ae) and in-licensed small molecule\u00a0inhibitors\u00a0(IAXOTM\u00a0compounds)\u00a0have been shown in proof-of-concept pre-clinical studies to treat\u00a0cancer\u00a0and prevent serious inflammatory diseases, respectively. Innaxon\u00a0continuously seeks further partnerships with academic, pharmaceutical and clinical research centresRead More","og_url":"https:\/\/www.innaxon.cz\/index.php\/about-innaxon\/","og_site_name":"Innaxon, s.r.o.","article_modified_time":"2025-08-20T10:54:38+00:00","og_image":[{"url":"https:\/\/www.innaxon.cz\/wp-content\/uploads\/2018\/04\/Innaxon-3-2.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.innaxon.cz\/index.php\/about-innaxon\/","url":"https:\/\/www.innaxon.cz\/index.php\/about-innaxon\/","name":"About Innaxon - Innaxon, s.r.o.","isPartOf":{"@id":"https:\/\/www.innaxon.cz\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.innaxon.cz\/index.php\/about-innaxon\/#primaryimage"},"image":{"@id":"https:\/\/www.innaxon.cz\/index.php\/about-innaxon\/#primaryimage"},"thumbnailUrl":"https:\/\/www.innaxon.cz\/wp-content\/uploads\/2018\/04\/Innaxon-3-2.jpg","datePublished":"2018-04-01T19:07:52+00:00","dateModified":"2025-08-20T10:54:38+00:00","breadcrumb":{"@id":"https:\/\/www.innaxon.cz\/index.php\/about-innaxon\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.innaxon.cz\/index.php\/about-innaxon\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.innaxon.cz\/index.php\/about-innaxon\/#primaryimage","url":"https:\/\/www.innaxon.cz\/wp-content\/uploads\/2018\/04\/Innaxon-3-2.jpg","contentUrl":"https:\/\/www.innaxon.cz\/wp-content\/uploads\/2018\/04\/Innaxon-3-2.jpg","width":1500,"height":750},{"@type":"BreadcrumbList","@id":"https:\/\/www.innaxon.cz\/index.php\/about-innaxon\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.innaxon.cz\/"},{"@type":"ListItem","position":2,"name":"About Innaxon"}]},{"@type":"WebSite","@id":"https:\/\/www.innaxon.cz\/#website","url":"https:\/\/www.innaxon.cz\/","name":"Innaxon, s.r.o.","description":"Targeting Innate Immunity For Therapeutic Benefit","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.innaxon.cz\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"}]}},"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.innaxon.cz\/index.php\/wp-json\/wp\/v2\/pages\/9","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.innaxon.cz\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.innaxon.cz\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.innaxon.cz\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.innaxon.cz\/index.php\/wp-json\/wp\/v2\/comments?post=9"}],"version-history":[{"count":21,"href":"https:\/\/www.innaxon.cz\/index.php\/wp-json\/wp\/v2\/pages\/9\/revisions"}],"predecessor-version":[{"id":643,"href":"https:\/\/www.innaxon.cz\/index.php\/wp-json\/wp\/v2\/pages\/9\/revisions\/643"}],"wp:attachment":[{"href":"https:\/\/www.innaxon.cz\/index.php\/wp-json\/wp\/v2\/media?parent=9"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}